Furthermore, the catalytic activity of TET2 was initially shown to be essential for the suppression of leukemogenesis [117], but a later study showed that both TET2 KO and catalytic mutant mice developed malignancies with distinct disease spectra: while TET2 KO mice developed both myeloid and lymphoid malignancies, the catalytic mutant mice almost exclusively developed myeloid malignancies [119]. Here, TET2 is linked to cancer.